# EDGAR Filing Document

**Accession Number:** 0001083446
**File Stem:** 0001628280-23-004894
**Filing Date:** 2023-2
**Character Count:** 52944
**Document Hash:** 4771dcd44ecc84729fedb56230700756
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-004894.hdr.sgml**: 20230223

**ACCESSION NUMBER**: 0001628280-23-004894

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 32

**CONFORMED PERIOD OF REPORT**: 20230223

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230223

**DATE AS OF CHANGE**: 20230223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apollo Medical Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001083446
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
- **IRS NUMBER:** 870042699
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37392
- **FILM NUMBER:** 23661127

**BUSINESS ADDRESS:**
- **STREET 1:** 1668 S. GARFIELD AVENUE
- **STREET 2:** 2ND FLOOR
- **CITY:** ALHAMBRA
- **STATE:** CA
- **ZIP:** 91801
- **BUSINESS PHONE:** (626) 282-0288

**MAIL ADDRESS:**
- **STREET 1:** 1668 S. GARFIELD AVENUE
- **STREET 2:** 2ND FLOOR
- **CITY:** ALHAMBRA
- **STATE:** CA
- **ZIP:** 91801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SICLONE INDUSTRIES INC
- **DATE OF NAME CHANGE:** 19990413

?xml version="1.0" ? ameh-20230223

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): February 23, 2023

**APOLLO MEDICAL HOLDINGS, INC.** 

(Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| Delaware | 001-37392 | 95-4472349 |
| (State or Other Jurisdiction | (Commission | (I.R.S. Employer |
| of Incorporation) | File Number) | Identification No.) |

---

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801

(Address of Principal Executive Offices) (Zip Code)

(626) 282-0288

Registrant's Telephone Number, Including Area Code

 

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) <u>Name of each exchange on which registered</u> <br> <u>Common Stock</u> <u>AMEH</u> <u>Nasdaq Capital Market</u>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.** |

---

On February 23, 2023, Apollo Medical Holdings, Inc. (the "Company") issued a press release announcing its financial results for the quarter and year ended December 31, 2022. The Company is also making available certain supplemental data for the fourth quarter and year ended December 31, 2022. A copy of the press release and supplemental data are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated herein by this reference.

In accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item 2.02, including Exhibit 99.1 and Exhibit 99.2 furnished herewith, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press Release of Apollo Medical Holdings, Inc., dated February 23, 2023.](exhibit991-pressrelease123.htm)</u> |
| 99.2 | <u>[Supplemental Data of Apollo Medical Holdings, Inc., dated February 23, 2023.](apollomedq4-ye2022earnin.htm)</u> |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **APOLLO MEDICAL HOLDINGS, INC.** | **APOLLO MEDICAL HOLDINGS, INC.** |
| Date: February 23, 2023 | By: | /s/ Thomas S. Lam |
|  | Name:<br>Title: | Thomas S. Lam, M.D., M.P.H.<br>Co-Chief Executive Officer and President |

---

## Exhibit 99.1

![b_montserrat002.jpg](b_montserrat002.jpg)

**Apollo Medical Holdings, Inc. Reports Fourth Quarter and Year-End 2022 Results**

**Company to Host Conference Call on Friday, Feb. 24, 2023, at 5:30 a.m. PT/8:30 a.m. ET** 

ALHAMBRA, Calif., February 23, 2022 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financial results for the fourth quarter and year ended December 31, 2022.

**Financial Highlights for the Year Ended December 31, 2022:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total revenue of $1.14 billion, an increase of 48% from $773.9 million for the prior year

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income attributable to ApolloMed of $49.0 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Earnings per share — diluted ("EPS — diluted") of $1.08

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $140.0 million, an increase of 5%, compared to $133.5 million for the prior year, resulting in an Adjusted EBITDA margin of 12.2%<sup>(1)</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash and cash equivalents of $288.0 million at December 31, 2022

<sup>(1)</sup> See "Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" below for additional information.

**Financial Highlights for Fourth Quarter 2022:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total revenue of $294.2 million, an increase of 51% from $195.1 million for the prior-year quarter

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss attributable to ApolloMed of $2.6 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $23.7 million, an increase of 54% from $15.4 million for the prior-year quarter

**Guidance:**

ApolloMed is providing the following guidance for total revenue, net income, EBITDA, Adjusted EBITDA, and EPS - diluted. The net income and EBITDA guidance ranges below include the impact of the excluded assets held by Allied Physicians of California, a Professional Medical Corporation's ("APC"), which are solely for the benefit of APC and its shareholders. Any gains or losses associated with these excluded assets do not have an impact on Adjusted EBITDA and EPS - diluted. These guidance assumptions are based on the Company's existing business, current view of existing market conditions and assumptions for the year ending December 31, 2023.

---

| | | |
|:---|:---|:---|
| *($ in millions)* | **2023 Guidance Range** | **2023 Guidance Range** |
|  | **Low** | **High** |
| Total revenue | $1300.0 | $1500.0 |
| Net income | $49.5 | $71.5 |
| EBITDA | $89.5 | $129.5 |
| Adjusted EBITDA | $120.0 | $160.0 |
| EPS – diluted | $0.95 | $1.20 |

---

See "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" below for additional information.

------

**Management Commentary:**

Brandon Sim, Co-Chief Executive Officer of ApolloMed, stated, "In 2022, we continued to position our Company for long-term growth while remaining focused on our mission of empowering physicians in the successful delivery of value-based care and driving superior outcomes for their patients. We were pleased with the strong financial and operational results our team achieved during 2022, including 48% growth on the top line and 5% growth in Adjusted EBITDA to $140.0 million, a margin of 12.2%. This was a result of strong organic membership growth in our core risk-bearing provider groups, favorable trends in membership mix, and participation in a value-based care model for the Medicare fee-for-service population.

"The investments made during 2022 position us for strong growth as we continue to execute against our operating priorities: scaling our care delivery model across core and new geographies, effectively taking on additional risk in our value-based contracts, and delivering industry-leading patient outcomes through our care delivery network and value-based care enablement platform.

"I would like to thank our team of over 1,300 employees for their dedication to ApolloMed's mission. We remain committed to empowering our providers, which will accelerate us towards a future where all Americans have access to high-quality, value-based and evidence-driven healthcare."

**GAAP Financial Review for the Year Ended December 31, 2022:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•*** Total revenue of $1.14 billion for the year ended December 31, 2022, an increase of 48%, compared to $773.9 million for the year ended December 31, 2021, primarily due to (i) an overall increase of $336.9 million in capitation revenue primarily driven by organic membership growth in ApolloMed's consolidated IPAs and participation in a value-based Medicare fee-for-service model, and (ii) an increase of $23.0 million in fee-for-service revenue from ApolloMed primary, multi-specialty, and ancillary care delivery entities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Capitation revenue, net, of $930.1 million for the year ended December 31, 2022, an increase of 57%, compared to $593.2 million for the year ended December 31, 2021. Capitation revenue represented 81% of total revenue for the year ended December 31, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•*** Net income of $50.5 million for the year ended December 31, 2022, an increase of 3%, compared to $49.3 million for the year ended December 31, 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•*** Net income attributable to ApolloMed of $49.0 million for the year ended December 31, 2022, compared to $73.9 million for the year ended December 31, 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•*** EPS - diluted of $1.08 for the year ended December 31, 2022, compared to $1.63 for the year ended December 31, 2021.

**GAAP Financial Review for the Fourth Quarter Ended December 31, 2022:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Total revenue of $294.2 million for the quarter ended December 31, 2022, an increase of 51%, compared to $195.1 million for the quarter ended December 31, 2021. This was primarily driven by organic membership growth in ApolloMed's consolidated IPAs and participation in a value-based Medicare fee-for-service model.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Capitation revenue, net, of $252.9 million for the quarter ended December 31, 2022, an increase of 63%, compared to $154.9 million for the quarter ended December 31, 2021. Capitation revenue represented 86% of total revenue for the quarter ended December 31, 2022.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Net income of $0.5 million for the quarter ended December 31, 2022, compared to net loss of $19.3 million for the quarter ended December 31, 2021, which was primarily a result of significantly lower unrealized losses in fair value of a payer partner's shares held as marketable securities and other investments of $2.8 million, which compares to $33.0 million in unrealized losses as a result of a 1-to-3 conversion of a payer partner's preferred shares to common stock in the prior-year period. These payer partner shares are deemed "Excluded Assets" that are solely for the benefit of APC and its shareholders and do not impact net income attributable to ApolloMed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•*** Net loss attributable to ApolloMed of $2.6 million for the quarter ended December 31, 2022, compared to net income attributable to ApolloMed of $13.8 million for the quarter ended December 31, 2021. The loss was primarily a result of a $13.1 million increase in income tax expense compared to the prior-year period.

**Non-GAAP Financial Review for the Year Ended December 31, 2022:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•*** EBITDA of $110.1 million for the year ended December 31, 2022, an increase of 11%, compared to $99.1 million for the year ended December 31, 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•*** Adjusted EBITDA of $140.0 million for the year ended December 31, 2022, an increase of 5%, compared to $133.5 million for year ended December 31, 2021.

**Non-GAAP Measures for the Fourth Quarter Ended December 31, 2022:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•*** EBITDA of $15.8 million for the quarter ended December 31, 2022, compared to EBITDA of negative $17.2 million for the quarter ended December 31, 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•*** Adjusted EBITDA of $23.7 million for the quarter ended December 31, 2022, an increase of 54%, compared to $15.4 million for the quarter ended December 31, 2021.

**Balance Sheet Highlights:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As of December 31, 2022, ApolloMed's cash and cash equivalents and investments in marketable securities were $293.6 million, working capital was $287.8 million, and total stockholders' equity increased to $555.0 million; from cash and cash equivalents and investments in marketable securities of $286.5 million, working capital of $283.4 million and total stockholders' equity of $460.5 million, respectively, as of December 31, 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In December 2022, ApolloMed's Board of Directors approved a share repurchase program authorizing the purchase of up to $50 million of its shares of common stock on the open market or through privately negotiated transactions. As of February 1, 2023, the Company had not yet purchased any shares under this share repurchase program. This repurchase program does not have an expiration date. The Board may suspend or discontinue the repurchase program at any time. This repurchase program does not obligate ApolloMed to make additional repurchases at any specific time or in any specific situation.

See "Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" below for additional information.

For more details on ApolloMed's financial results for the year ended December 31, 2022, please refer to ApolloMed's Annual Report on Form 10-K to be filed with the U.S. Securities Exchange Commission ("SEC"), which is accessible at <u>www.sec.gov</u>.

------

**Conference Call and Webcast Information:**

ApolloMed will host a conference call at 5:30 a.m. PT/8:30 a.m. ET today (Friday, February 24, 2023), during which management will discuss the results of the fourth quarter and year ended December 31, 2022. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:

U.S. & Canada (Toll-Free): (877) 407-9753 <br> International (Toll): (201) 493-6739

<br>The conference call can also be accessed at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=0Kd2PA99.

An accompanying slide presentation will be available in PDF format on the "IR Calendar" page of the Company's website (<u>https://www.apollomed.net/investors/news-events/ir-calendar</u>) after issuance of the earnings release and will be filed as an exhibit to ApolloMed's current report on Form 8-K to be filed with the SEC, accessible at <u>www.sec.gov</u>.

Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.

**Note About Consolidated Entities**

The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities ("VIEs") in which the Company is the primary beneficiary. Noncontrolling interests represent third party equity ownership interests in the Company's consolidated entities (including certain VIEs). The amount of net income attributable to noncontrolling interests is disclosed in the Company's consolidated statements of income.

**Note About Stockholders' Equity, Certain Treasury Stock and Earnings Per Share**

As of December 31, 2022, 140,954 holdback shares had not been issued to certain former shareholders of the Company's subsidiary, Network Medical Management, Inc. ("NMM"), who were NMM shareholders at the time of closing of the merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed's common stock and warrants as contemplated under that certain Agreement and Plan of Merger, dated December 21, 2016, among ApolloMed, NMM, Apollo Acquisition Corp. ("Merger Subsidiary") and Kenneth Sim, M.D., as amended, pursuant to which Merger Subsidiary merged with and into NMM, with NMM as the surviving corporation. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the merger. The Company's consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and ApolloMed is legally obligated to issue these shares in connection with the merger.

Shares of ApolloMed's common stock owned by APC, a VIE of the Company, are legally issued and outstanding but excluded from shares of common stock outstanding in the Company's consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. Such shares, therefore, are not included in the number of shares of common stock outstanding used to calculate the Company's earnings per share.

**About Apollo Medical Holdings, Inc.**

ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.

Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models. For more information, please visit <u>www.apollomed.net</u>.

------

**Forward-Looking Statements**

*This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company's guidance for the year ending December 31, 2022, continued growth, acquisition strategy, ability to deliver sustainable long-term value, ability to respond to the changing environment, operational focus, strategic growth plans and merger integration efforts, as well as the impact of the COVID-19 pandemic on the Company's business, operations and financial results. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the SEC, including, without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, which will be filed with the SEC, and any subsequent quarterly reports on Form 10-Q.*

**FOR MORE INFORMATION, PLEASE CONTACT:**

Investor Relations<br>(626) 943-6491<br><u>investors@apollomed.net</u>

Carolyne Sohn, The Equity Group<br>(408) 538-4577<br><u>csohn@equityny.com</u>

------

---

| | | |
|:---|:---|:---|
| **APOLLO MEDICAL HOLDINGS, INC.** | **APOLLO MEDICAL HOLDINGS, INC.** | **APOLLO MEDICAL HOLDINGS, INC.** |
| **CONSOLIDATED BALANCE SHEETS** | **CONSOLIDATED BALANCE SHEETS** | **CONSOLIDATED BALANCE SHEETS** |
| (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) | (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) | (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) |
|  | **December 31,** | **December 31,** |
|  | **2022** | **2021** |
| **Assets** |  |  |
| **Current assets** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $288027 | $233097 |
| &nbsp;&nbsp;&nbsp;Investment in marketable securities | 5567 | 53417 |
| &nbsp;&nbsp;&nbsp;Receivables, net | 52629 | 10608 |
| &nbsp;&nbsp;&nbsp;Receivables, net – related parties | 65147 | 69376 |
| &nbsp;&nbsp;Income taxes receivable | 4015 |  |
| &nbsp;&nbsp;&nbsp;Other receivables | 1834 | 9647 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 14798 | 18637 |
| &nbsp;&nbsp;&nbsp;Loans receivable | 996 |  |
| &nbsp;&nbsp;&nbsp;Loans receivable - related party | 2125 | 4000 |
| Total current assets | 435138 | 398782 |
| **Non-current assets** |  |  |
| &nbsp;&nbsp;&nbsp;Land, property and equipment, net | 108536 | 53186 |
| &nbsp;&nbsp;&nbsp;Intangible assets, net | 76861 | 82807 |
| &nbsp;&nbsp;&nbsp;Goodwill | 275675 | 253039 |
| &nbsp;&nbsp;&nbsp;Loans receivable |  | 569 |
| &nbsp;&nbsp;&nbsp;Investments in other entities – equity method | 40299 | 41715 |
| &nbsp;&nbsp;&nbsp;Investments in privately held entities | 896 | 896 |
| &nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 20444 | 15441 |
| &nbsp;&nbsp;&nbsp;Other assets | 6056 | 5928 |
| Total non-current assets | 528767 | 453581 |
| **Total assets**<sup>(1)</sup> | $963905 | $852363 |
| **Liabilities, mezzanine equity and stockholders' equity** |  |  |
| **Current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | $49562 | $43951 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fiduciary accounts payable | 8065 | 10534 |
| &nbsp;&nbsp;&nbsp;&nbsp;Medical liabilities | 84253 | 55783 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable |  | 652 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividend payable | 664 | 556 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance lease liabilities | 594 | 486 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | 3572 | 2629 |

---

------

---

| | | |
|:---|:---|:---|
| | **December 31,<br>2022** | **December 31,<br>2021** |
| &nbsp;&nbsp;&nbsp;Current portion of long-term debt | 619 | 780 |
| Total current liabilities | 147329 | 115371 |
| **Non-current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Deferred tax liability | 3042 | 9127 |
| &nbsp;&nbsp;&nbsp;Finance lease liabilities, net of current portion | 1275 | 973 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities, net of current portion | 19915 | 13198 |
| &nbsp;&nbsp;&nbsp;Long-term debt, net of current portion and deferred financing costs | 203389 | 182917 |
| &nbsp;&nbsp;&nbsp;Other long-term liabilities | 20260 | 14777 |
| Total non-current liabilities | 247881 | 220992 |
| **Total liabilities**<sup>(1)</sup> | 395210 | 336363 |
| **Mezzanine equity** |  |  |
| &nbsp;&nbsp;&nbsp;Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation | 13682 | 55510 |
| **Stockholders' equity** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and zero outstanding |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock); 555,555 issued and zero outstanding |  |  |
| &nbsp;&nbsp;Common stock, $0.001 par value per share; 100,000,000 shares authorized, 46,575,699 and 44,630,873 shares outstanding, excluding 10,299,259 and 10,925,702 treasury shares, at December 31, 2022, and December 31, 2021, respectively | 47 | 45 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 360097 | 310876 |
| &nbsp;&nbsp;&nbsp;Retained earnings | 192678 | 143629 |
|  | 552822 | 454550 |
| &nbsp;&nbsp;&nbsp;Non-controlling interest | 2191 | 5940 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 555013 | 460490 |
| **Total liabilities, mezzanine equity and stockholders' equity** | $963905 | $852363 |

---

<sup>(1)</sup> The Company's consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). The consolidated balance sheets include total assets that can be used only to settle obligations of the Company's consolidated VIEs totaling $505.8 million and $567.0 million as of December 31, 2022 and December 31, 2021, respectively, and total liabilities of the Company's consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $129.7 million and $91.7 million as of December 31, 2022 and December 31, 2021, respectively. These VIE balances do not include $304.8 million of investment in affiliates and $30.3 million of amounts due from affiliates as of December 31, 2022 and $802.8 million of investment in affiliates and $6.6 million of amounts due from affiliates as of December 31, 2021 as these are eliminated upon consolidation and not presented within the consolidated balance sheets.

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **APOLLO MEDICAL HOLDINGS, INC.** | **APOLLO MEDICAL HOLDINGS, INC.** | **APOLLO MEDICAL HOLDINGS, INC.** | **APOLLO MEDICAL HOLDINGS, INC.** | **APOLLO MEDICAL HOLDINGS, INC.** |
| **CONSOLIDATED STATEMENTS OF INCOME** | **CONSOLIDATED STATEMENTS OF INCOME** | **CONSOLIDATED STATEMENTS OF INCOME** | **CONSOLIDATED STATEMENTS OF INCOME** | **CONSOLIDATED STATEMENTS OF INCOME** |
| (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) | (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) | (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) | (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) | (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) |
|  | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Year Ended<br> December 31,** | **Year Ended<br> December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| **Revenue** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Capitation, net | $252878 | $154874 | $930131 | $593224 |
| &nbsp;&nbsp;&nbsp;Risk pool settlements and incentives | 15537 | 17481 | 117254 | 111627 |
| &nbsp;&nbsp;&nbsp;Management fee income | 10607 | 9614 | 41094 | 35959 |
| &nbsp;&nbsp;&nbsp;Fee-for-service, net | 13823 | 11596 | 49517 | 26564 |
| &nbsp;&nbsp;&nbsp;Other income | 1363 | 1535 | 6167 | 6541 |
| Total revenue | 294208 | 195100 | 1144163 | 773915 |
| **Operating expenses** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cost of services, excluding depreciation and amortization | 253119 | 171839 | 944685 | 596142 |
| &nbsp;&nbsp;&nbsp;General and administrative expenses | 24446 | 16601 | 77670 | 62077 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 4063 | 4412 | 17543 | 17517 |
| Total expenses | 281628 | 192852 | 1039898 | 675736 |
| **Income from operations** | 12580 | 2248 | 104265 | 98179 |
| **Other (expense) income** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Income (loss) from equity method investments | 1225 | (626) | 5622 | (4306) |
| &nbsp;&nbsp;Gain on sale of equity method investment |  |  |  | 2193 |
| &nbsp;&nbsp;&nbsp;Interest expense | (2572) | (1051) | (7920) | (5394) |
| &nbsp;&nbsp;&nbsp;Interest income | 1286 | 240 | 1976 | 1571 |
| &nbsp;&nbsp;Unrealized loss on investments | (3680) | (33571) | (21271) | (10745) |
| &nbsp;&nbsp;&nbsp;Other income (expense) | 1616 | 10330 | 3944 | (3750) |
| Total other (expense) income, net | (2125) | (24678) | (17649) | (20431) |
| **Income (loss) before provision for income taxes** | 10455 | (22430) | 86616 | 77748 |
| Provision for (benefit from) income taxes | 9984 | (3121) | 36085 | 28454 |
| **Net income (loss)** | 471 | (19309) | 50531 | 49294 |
| Net income (loss) attributable to noncontrolling interests | 3071 | (33079) | 1482 | (24564) |
| **Net (loss) income attributable to Apollo Medical Holdings, Inc.** | $(2600) | $13770 | $49049 | $73858 |
| **(Losses) earnings per share – basic** | $(0.06) | $0.31 | $1.09 | $1.69 |
| **(Losses) earnings per share – diluted** | $(0.06) | $0.30 | $1.08 | $1.63 |

---

------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **<u>Reconciliation of Net Income to EBITDA and Adjusted EBITDA</u>** | **<u>Reconciliation of Net Income to EBITDA and Adjusted EBITDA</u>** | **<u>Reconciliation of Net Income to EBITDA and Adjusted EBITDA</u>** | **<u>Reconciliation of Net Income to EBITDA and Adjusted EBITDA</u>** | **<u>Reconciliation of Net Income to EBITDA and Adjusted EBITDA</u>** | **<u>Reconciliation of Net Income to EBITDA and Adjusted EBITDA</u>** | **<u>Reconciliation of Net Income to EBITDA and Adjusted EBITDA</u>** | **<u>Reconciliation of Net Income to EBITDA and Adjusted EBITDA</u>** | |
| | **Three Months Ended<br> December 31,** | **Three Months Ended<br> December 31,** | **Three Months Ended<br> December 31,** | | **Year Ended<br> December 31,** | **Year Ended<br> December 31,** | **Year Ended<br> December 31,** | |
| *(in thousands)* | **2022** |  | **2021** |  | **2022** |  | **2021** |  |
| Net income (loss) | $471 |  | $(19309) |  | $50531 |  | $49294 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 2572 |  | 1051 |  | 7920 |  | 5394 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | (1286) |  | (240) |  | (1976) |  | (1571) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for (benefit from) income taxes | 9984 |  | (3121) |  | 36085 |  | 28454 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 4063 |  | 4412 |  | 17543 |  | 17517 |  |
| **EBITDA** | $15804 |  | $(17207) |  | $110103 |  | $99088 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income from equity method investments | (253) |  | (28) |  | (746) |  | (268) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of equity method investment |  |  |  |  |  |  | (2193) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | 1927 | <sup>(1)</sup> | (788) | <sup>(3)</sup> | 3309 | <sup>(2)</sup> | (1720) | <sup>(3)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 5623 |  | 2423 |  | 16101 |  | 6745 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;APC excluded assets costs | 550 |  | 30956 |  | 11259 |  | 31876 |  |
| **Adjusted EBITDA** | $23651 |  | $15356 |  | $140026 |  | $133528 |  |

---

<sup>(1)</sup> Other, net for the three months ended December 31, 2022 relates to changes in the fair value of our mandatory purchase of investments and contingent considerations.

<sup>(2)</sup> Other, net for the year ended December 31, 2022 relates to transaction costs incurred and changes in the fair value of our mandatory purchase of investments and contingent considerations.

<sup>(3)</sup> Other, net for the three months and year ended December 31, 2021 relates to stimulus checks received in 2021.

---

| | | |
|:---|:---|:---|
| **<u>Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA</u>** | **<u>Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA</u>** | **<u>Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA</u>** |
| *(in thousands)* | **2023 Guidance Range** | **2023 Guidance Range** |
|  | **Low** | **High** |
| Net income | $49500 | $71500 |
| &nbsp;&nbsp;Interest expense | 1000 | 1000 |
| &nbsp;&nbsp;Provision for income taxes | 23000 | 38000 |
| &nbsp;&nbsp;Depreciation and amortization | 16000 | 19000 |
| **EBITDA** | 89500 | 129500 |
| &nbsp;&nbsp;Income from equity method investments | (750) | (750) |
| &nbsp;&nbsp;Other, net | 3250 | 3250 |
| &nbsp;&nbsp;Stock-based compensation | 16000 | 16000 |
| &nbsp;&nbsp;APC excluded assets costs | 12000 | 12000 |
| **Adjusted EBITDA** | $120000 | $160000 |

---

------

**Use of Non-GAAP Financial Measures**

This press release contains the non-GAAP financial measures EBITDA and adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles ("GAAP") is net income. These measures are not in accordance with, or alternatives to GAAP, and may be different from other non-GAAP financial measures used by other companies. The Company uses adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, and APC excluded assets costs. Beginning in the third quarter ended September 30, 2022, the Company has revised the calculation for Adjusted EBITDA to exclude provider bonus payments and losses from recently acquired IPAs, which it believes to be more reflective of its business.

The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company's ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.

## Exhibit 99.2

![](apollomedq4-ye2022earnin001.jpg)

------

![](apollomedq4-ye2022earnin002.jpg)

Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial condition, operating results, plans, objectives, expectations and intentions, expansion plans, integration of acquired companies and any projections of earnings, revenue, EBITDA, Adjusted EBITDA or other financial items, such as the Company's projected capitation and future liquidity, and may be identified by the use of forward-looking terms such as "anticipate," "could," "can," "may," "might," "potential," "predict," "should," "estimate," "expect," "project," "believe," "plan," "envision," "intend," "continue," "target," "seek," "will," "would," and the negative of such terms, other variations on such terms or other similar or comparable words, phrases or terminology. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the U.S. Securities and Exchange Commission (the "SEC"), including without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and subsequent Quarterly Reports on Form 10-Q. Because the factors referred to above could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, you should not place undue reliance on any such forward-looking statements. Any forward-looking statements speak only as of the date of this presentation and, unless legally required, the Company does not undertake any obligation to update any forward-looking statement, as a result of new information, future events or otherwise. 2www.apollomed.net

------

![](apollomedq4-ye2022earnin003.jpg)

14\* managed IPAs and medical groups 1.3M managed lives Company Overview 3 11,000+ contracted physicians 25+ years in operation ApolloMed is a tech-powered, value-based healthcare network that serves all Americans. • We provide quality care to underserved communities. • We enable best in class clinical outcomes within our value-based care provider organizations. • Our value-based enablement suite positions us to scale rapidly nationwide. ApolloMed At-A-Glance Ticker NASDAQ: AMEH Headquarters Alhambra, California Recent Stock Price (as of 2/21/2023) $33.22 Market Cap (as of 2/21/2023) $1.9 billion Common Shares Outstanding (as of 2/16/2023) 57.4 million Book Value Per Common Share $9.66 TTM Revenues $1.14 billion IPA: independent physician association \*As of 12/31/2022

------

![](apollomedq4-ye2022earnin004.jpg)

Strong YE 2022 financial results Q4/YE and Recent Highlights Expected to close in Q1 2023: • Entered into a definitive agreement to acquire 100% of For Your Benefit ("FYB"), as well as certain managed care assets Strategic transactions www.apollomed.net \*See "Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" slides for more information. Please note that beginning the third quarter ended September 30, 2022, the Company has revised the calculation for Adjusted EBITDA to exclude addbacks related to provider bonus payments and losses from recently acquired IPAs, which it believes to be more reflective of its business. Revenue $1.1B 48% Net income attr. to AMEH $49.0M EPS – diluted $1.08 Adj. EBITDA\* $140.0M 5% 4 • Orma Health • Jade Health Care Medical Group • All American Medical Group ("AAMG") • Valley Oaks Medical Group ("VOMG") Poised for growth with the closing of several strategic transactions in 2022:

------

![](apollomedq4-ye2022earnin005.jpg)

Historical Financial Profile www.apollomed.net $54.2 $102.8 $133.5 $140.0 $140.0 2019 2020 2021 2022 2023\* $561 $687 $774 $1,144 $1,400 Historical revenue growth ($ in millions) \* midpoint of 2023 guidance range ($ in millions) Historical Adjusted EBITDA(1) 2019 2020 2021 5 2022 2023\* 2021 benefitted from tailwinds of lower utilization during the peak of the COVID-19 pandemic, while 2022 was impacted by higher cost of services due to utilization returning to near pre-pandemic levels \* midpoint of 2023 guidance range (1) See "Use of Non-GAAP Financial Measures" slide for more information. 26% CAGR from 2019- 2023E

------

![](apollomedq4-ye2022earnin006.jpg)

Summary of Selected Financial Results www.apollomed.net 6 Three Months Ended December 31, Year Ended December 31, $ in 000s except per share data 2022 2021 2022 2021 Revenue Capitation, net $252,878 $154,874 $930,131 $593,224 Risk pool settlements and incentives 15,537 17,481 117,254 111,627 Management fee income 10,607 9,614 41,094 35,959 Fee-for-service, net 13,823 11,596 49,517 26,564 Other income 1,363 1,535 6,167 6,541 Total revenue 294,208 195,100 1,144,163 773,915 Total expenses 281,628 192,852 1,039,898 675,736 Income from operations 12,580 2,248 104,265 98,179 Net income (loss) 471 (19,309) 50,531 49,294 Net income (loss) attributable to noncontrolling interests 3,071 (33,079) 1,482 (24,564) Net (loss) income attributable to ApolloMed $(2,600) $13,770 $49,049 $73,858 (Losses) earnings per share – diluted $(0.06) $0.30 $1.08 $1.63

------

![](apollomedq4-ye2022earnin007.jpg)

Capitation, net –Capitation from payers (including government payers) for medical services, typically pre- paid monthly based on number of enrollees 0.5% 4.3% 3.6% 10.3% 81.3% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Capitation, net Risk Pool Settlements & Incentives Management Fee income Fee-for-service, net Other Income Revenue Breakdown 7 A B C D www.apollomed.net For the year ended December 31, 2022 Risk Pool Settlements & Incentives - Full and shared risk capitation arrangements with specific payers and hospitals Management Fee Income - Fees earned from providing value-based enablement services (including but not limited to management, advisory, healthcare staffing, administrative and other non-medical services) Fee-for-service - Professional charges for medical services

------

![](apollomedq4-ye2022earnin008.jpg)

55% 25% 15% 5% FULL YEAR 2022 (% OF TOTAL REVENUE) Medicare Medicaid Commercial Other Third Parties Business Mix by Payer Type 8www.apollomed.net

------

![](apollomedq4-ye2022earnin009.jpg)

Balance Sheet Highlights 9 $ in millions 12/31/2022 12/31/2021 $ Change % Change Cash and cash equivalents and investments in marketable securities $293.6 $286.5 $7.1 2% Working capital $287.8 $283.4 $4.4 2% Total stockholders' equity $555.0 $460.5 $94.5 21% www.apollomed.net

------

![](apollomedq4-ye2022earnin010.jpg)

2023 Guidance 10www.apollomed.net $ in millions, except for per share information Actual YE 2022 Results 2023 Guidance Range Total Revenue $1,144.2 $1,300.0-$1,500.0 Net Income(1) $50.5 $49.5-$71.5 EBITDA(1,2) $110.1 $89.5-$129.5 Adjusted EBITDA(2) $140.0 $120.0-$160.0 EPS – Diluted $1.08 $0.95-$1.20 (1) Net income and EBITDA forecast includes the impact of APC excluded assets, which assume no change in value. (2) See "Reconciliation of Net Income to EBITDA and Adjusted EBITDA," "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" slides for more information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" on slide 2.

------

![](apollomedq4-ye2022earnin011.jpg)

Reconciliation of Net Income to EBITDA and Adjusted EBITDA 11www.apollomed.net (1) See "Use of Non-GAAP Financial Measures" slide for more information. (2) Other, net for the three months ended December 31, 2022, relates to changes in the fair value of mandatory purchase of investments and contingent considerations. (3) Other, net for the year ended December 31, 2022, relates to transaction costs incurred and changes in the fair value of mandatory purchase of investments and contingent considerations. (4) Other, net for the three months and year ended December 31, 2021, relates to stimulus checks received in 2021. ($ in millions) 2022 2021 2022 2021 Net income $0.5 $(19.3) $50.5 $49.3 Interest expense 2.6 1.1 7.9 5.4 Interest income (1.3) (0.2) (2.0) (1.6) (Benefit from) provision for income taxes 10.0 (3.1) 36.1 28.5 Depreciation and amortization 4.0 4.4 17.5 17.5 EBITDA(1) $15.8 $(17.2) $110.1 $99.1 Income from equity method investments $(0.3) $(0.0) $(0.7) $(0.3) Gain on sale of equity method investment - - - (2.2) Other, net 1.9 (2) (0.8) (3) 3.3 (4) (1.7) (3) Stock-based compensation 5.6 2.4 16.1 6.7 APC excluded assets costs 0.6 31.0 11.3 31.9 Adjusted EBITDA(1) $23.7 $15.4 $140.0 $133.5 Year Ended December 31, Three Months Ended December 31,

------

![](apollomedq4-ye2022earnin012.jpg)

Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA 12www.apollomed.net (1) See "Use of Non-GAAP Financial Measures" slide for more information. ($ in millions) Low High Net income $49.5 $71.5 Interest expense 1.0 1.0 Provision for income taxes 23.0 38.0 Depreciation and amortization 16.0 19.0 EBITDA(1) $89.5 $129.5 Income from equity method investments $(0.8) $(0.8) Other, net 3.3 3.3 Stock-based compensation 16.0 16.0 APC excluded assets costs 12.0 12.0 Adjusted EBITDA(1) $120.0 $160.0 Year Ending December 31, 2023

------

![](apollomedq4-ye2022earnin013.jpg)

www.apollomed.net 13 Year Ended December 31, 2022 Year Ended December 31, 2021 Year Ended December 31, 2020 $ in millions ApolloMed Consolidated Excluded Assets ApolloMed Assets ApolloMed Consolidated Excluded Assets ApolloMed Assets ApolloMed Consolidated Excluded Assets ApolloMed Assets Revenue Capitation, net $930.1 - 930.1 $593.2 - 593.2 $557.3 - 557.3 Risk pool settlements and incentives 117.3 - 117.3 111.6 - 111.6 77.4 - 77.4 Management fee income 41.1 - 41.1 36.0 - 36.0 34.9 - 34.9 Fee-for-service, net 49.5 - 49.5 26.6 - 26.6 12.7 - 12.7 Other income 6.2 - 6.2 6.5 - 6.5 5.0 - 5.0 Total revenue 1,144.2 - 1,144.2 773.9 - 773.9 687.3 - 687.3 Total operating expenses 1,039.9 2.4 1037.6 675.7 2.6 673.1 606.7 2.1 604.6 Income (loss) from operations 104.3 (2.4) 106.6 98.2 (2.6) 100.8 80.6 (2.1) 82.7 Total other (expense) income, net (17.6) (10.3) (7.3) (20.3) (10.8) (9.5) 97.9 102.9 (5.0) Net income (loss) $50.5 (18.4) 68.9 $49.3 (13.4) 62.7 $122.3 100.8 21.5 Summary of Selected Financial Results – Breaking Out Excluded Assets

------

![](apollomedq4-ye2022earnin014.jpg)

www.apollomed.net 14 Summary Balance Sheet – Breaking Out Excluded Assets $ in millions ApolloMed Consolidated Excluded Assets ApolloMed Assets ApolloMed Consolidated Excluded Assets ApolloMed Assets ApolloMed Consolidated Excluded Assets ApolloMed Assets Current assets Cash and cash equivalents $288.0 30.2 257.8 $233.1 62.5 170.6 $193.5 38.8 154.7 Investments in marketable securities 5.6 4.5 1.1 53.4 49.1 4.3 67.7 66.5 1.2 Receivables, net 52.6 - 52.6 10.6 - 10.6 7.1 - 7.1 Receivables - related parties and loan receivable - related party 67.2 - 67.2 73.4 4.0 69.4 49.4 - 49.4 Other receivables, prepaid expenses and other current assets, and loans receivable 17.6 0.8 16.8 28.2 0.9 27.3 21.0 - 21.0 Income taxes receivable 4.0 (1.1) 5.1 - - - - - - Total current assets 435.0 34.4 400.6 398.7 116.5 282.2 338.7 105.3 233.4 Non-current assets Land, property, and equipment, net 108.5 101.3 7.2 53.2 42.1 11.1 29.9 24.5 5.4 Goodwill and intangibles 352.6 - 352.6 335.8 - 335.8 326.1 - 326.1 Loan receivable and loan receivable - related parties, net of current portion - - - 0.6 - 0.6 4.6 4.1 0.5 Investments in other entities and privately held entities 41.2 27.6 13.6 42.6 25.0 17.6 80.4 62.0 18.4 Other assets and right-of-use assets 26.5 3.2 23.3 21.3 - 21.3 37.5 15.7 21.8 Total non-current assets 528.8 132.1 396.7 453.5 67.1 386.4 478.5 106.3 372.2 Total assets $963.8 166.5 797.3 $852.2 183.6 668.6 $817.2 211.6 605.6 December 31, 2022 December 31, 2021 December 31, 2020

------

![](apollomedq4-ye2022earnin015.jpg)

www.apollomed.net 15 Summary Balance Sheet – Breaking Out Excluded Assets (continued) $ in millions ApolloMed Consolidated Excluded Assets ApolloMed Assets ApolloMed Consolidated Excluded Assets ApolloMed Assets ApolloMed Consolidated Excluded Assets ApolloMed Assets Current liabilities Fiduciary payable, accounts payable and accrued liabilities $57.7 2.8 54.9 $54.5 0.3 54.2 $45.7 - 45.7 Medical liabilities 84.3 - 84.3 55.8 - 55.8 50.3 - 50.3 Income taxes payable - - - 0.7 - 0.7 4.2 - 4.2 Dividend payable 0.7 - 0.7 0.6 - 0.6 0.5 - 0.5 Finance and operating lease liabilities 4.2 - 4.2 3.1 - 3.1 3.3 - 3.3 Current portion of long-term debt 0.6 0.6 - 0.8 0.5 0.3 10.9 0.2 10.7 Total current liabilities 147.5 3.4 144.1 115.5 0.8 114.7 114.9 0.2 114.7 Non-current liabilities Deferred tax liability 3.00 0.90 2.1 9.1 - 9.1 11.0 - 11.0 Finance and operating lease liabilities, net of current portion 21.20 - 21.2 14.2 - 14.2 16.2 - 16.2 Other long-term liabilities 203.40 26.60 176.8 14.8 0.9 13.9 - - - Long-term debt, net of current portion and deferred financing costs 20.30 - 20.3 182.9 7.1 175.8 230.2 7.4 222.8 Total non-current liabilities 247.9 27.5 220.4 221.0 8.0 213.0 257.4 7.4 250.0 Total liabilities 395.4 30.9 364.5 336.5 8.8 327.7 372.3 7.6 364.7 Total mezzanine equity and stockholder's equity $568.40 135.6 432.8 $515.7 174.8 340.9 $444.9 204.0 240.9 December 31, 2022 December 31, 2021 December 31, 2020

------

![](apollomedq4-ye2022earnin016.jpg)

Use of Non-GAAP Financial Measures This presentation contains the non-GAAP financial measures EBITDA and Adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles ("GAAP") is net income. These measures are not in accordance with, or alternatives to GAAP, and may be different from other non-GAAP financial measures used by other companies. The Company uses Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to- period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring transactions, stock-based compensation, and APC excluded assets costs. Beginning in the third quarter ended September 30, 2022, the Company has revised the calculation for Adjusted EBITDA to exclude provider bonus payments and losses from recently acquired IPAs, which it believes to be more reflective of its business. The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company's ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non- GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above. 16www.apollomed.net

------

![](apollomedq4-ye2022earnin017.jpg)

17 For inquiries, please contact: ApolloMed Investor Relations (626) 943-6491 investors@apollomed.net Carolyne Sohn, The Equity Group (408) 538-4577 csohn@equityny.com

------